8,669 results match your criteria Lymphoma Cutaneous T-Cell


Extensive eczema herpeticum in a previously well child.

Int J Emerg Med 2022 May 21;15(1):21. Epub 2022 May 21.

Department of Pediatrics, Salmaniya Medical Complex, Manama, Bahrain.

Background: Eczema herpeticum, also known as Kaposi varicelliform eruption, is a potentially life-threatening disseminated cutaneous viral infection. In the majority of cases, this condition develops as a complication in patients with atopic dermatitis. However, it may arise in a wide spectrum of pre-existing skin conditions, including psoriasis, seborrheic dermatitis, contact dermatitis, cutaneous T cell lymphoma, pemphigus vulgaris, and others. Read More

View Article and Full-Text PDF

Suberoylanilide Hydroxamic Acid (SAHA) Treatment Reveals Crosstalk Among Proteome, Phosphoproteome, and Acetylome in Nasopharyngeal Carcinoma Cells.

Front Genet 2022 3;13:873840. Epub 2022 May 3.

Department of Oncology, NHC Key Laboratory of Cancer Proteomics, XiangYa Hospital, Central South University, Changsha, China.

Suberoylanilide hydroxamic acid (SAHA), a famous histone deacetylase (HDAC) inhibitor, has been utilized in clinical treatment for cutaneous T-cell lymphoma. Previously, the mechanisms underlying SAHA anti-tumor activity mainly focused on acetylome. However, the characteristics of SAHA in terms of other protein posttranslational modifications (PTMs) and the crosstalk between various modifications are poorly understood. Read More

View Article and Full-Text PDF

Prevalence of T-cell antigen losses in mycosis fungoides and CD30-positive cutaneous T-cell lymphoproliferations in a series of 153 patients.

Pathology 2022 May 13. Epub 2022 May 13.

Department of Pathology, APHP, Henri Mondor Hospital, Creteil, France; Paris-Est Creteil University and INSERM U955 Team NFL, Creteil, France. Electronic address:

Mycosis fungoides (MF) and primary cutaneous CD30-positive T-cell lymphoproliferative disorders (CD30LPD) are the most frequent primary cutaneous T-cell lymphomas. Our objective was to study pan-T-cell antigens and PD-1 expression in a large cohort of MF and CD30LPD with a special interest in antigen losses as a diagnostic tool. We retrospectively reviewed 160 consecutive samples from 153 patients over a 3 year period, including 104 with MF and 49 with CD30LPD. Read More

View Article and Full-Text PDF

Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias.

Front Oncol 2022 29;12:858426. Epub 2022 Apr 29.

Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States.

T-Cell malignancies are a group of heterogeneous disorders composed of primary cutaneous T-cell lymphomas (CTCLs), peripheral T-cell lymphomas (PTCLs), and T-cell leukemias, including T-cell large granular lymphocytic leukemia (T-LGLL). Cases of patients with combined T-cell malignancies and plasma cell dyscrasias (PCD) are reported in the literature, but these are mostly limited to case reports or small case series with <10 patients. Here, we described the clinical course of 26 patients and report baseline characteristics and clinical outcomes including overall survival (OS), progression-free survival (PFS), and objective response rates (ORRs) in this unique population. Read More

View Article and Full-Text PDF

Healthcare Disparities in the Management of Indolent Mycosis Fungoides.

Cureus 2022 Apr 13;14(4):e24098. Epub 2022 Apr 13.

Dermatology, Elias Emergency University Hospital, Bucharest, ROU.

Mycosis fungoides represents the most common cutaneous T-cell lymphoma, clinically manifested with evolving skin lesions, including patches, plaques, tumors, and erythroderma. Early diagnosis remains difficult to establish because it mimics several benign skin conditions, but maintaining a high index of suspicion for the disease is essential in preventing the progression of a potentially fatal disease. We report the case of a 69-year-old female who presented in our dermatology clinic in 2018 with scaly, indurated, itchy erythematous-violaceus patches and plaques, and tumors disseminated throughout the skin evolving for nine years. Read More

View Article and Full-Text PDF

Primary cutaneous lymphoma: the 2018 update of the WHO-EORTC classification.

Authors:
Rein Willemze

Presse Med 2022 May 12:104126. Epub 2022 May 12.

Department of Dermatology, Leiden University Medical Center, Leiden, The Netherlands. Electronic address:

Primary cutaneous lymphomas are a heterogeneous group of cutaneous T-cell lymphomas (CTCL) and cutaneous B-cell lymphomas (CBCL) that present in the skin with no evidence of extracutaneous disease at the time of diagnosis. In the last decade the 2005 WHO-EORTC consensus classification has served as a golden standard for the diagnosis and classification of these conditions. Recently, an updated version of the WHO-EORTC was published. Read More

View Article and Full-Text PDF

New developments in skin-directed treatments of cutaneous T-cell lymphoma.

Presse Med 2022 May 10:104125. Epub 2022 May 10.

Division of Dermatology, Rabin Medical Center-Beilinson Hospital, Petach Tikva; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address:

The therapeutic approach for mycosis fungoides, the most common type of primary cutaneous T-cell lymphoma, is based mainly on the stage of the disease, and skin-directed treatment is recommended by all international guidelines as the first-line treatment in early-stage disease. Skin-directed treatments may be also given in combination with systemic therapies in early-stage mycosis fungoides patients recalcitrant to different types of skin-directed treatments, or in certain patients with high-risk features. Advanced-stage mycosis fungoides is treated mainly with systemic treatments, which may be combined with skin-directed treatments. Read More

View Article and Full-Text PDF

Chlormethine Gel Versus Chlormethine Ointment for Treatment of Patients with Mycosis Fungoides: A Post-Hoc Analysis of Clinical Trial Data.

Am J Clin Dermatol 2022 May 10. Epub 2022 May 10.

Division of Dermatology, Rabin Medical Center, Beilinson Hospital, Petah Tikvah, Israel.

Background: Chlormethine gel was approved for treatment of mycosis fungoides, the most common cutaneous T-cell lymphoma, on the basis of results from study 201 and study 202. A post-hoc analysis of study 201 found interesting trends regarding improved efficacy of chlormethine gel vs ointment and noted a potential association between dermatitis and clinical response.

Objective: To expand these results by performing a post-hoc analysis of study 202. Read More

View Article and Full-Text PDF

Genetically driven CD39 expression affects Sezary cell viability, IL-2 production and detects two patient subsets with distinct prognosis.

J Invest Dermatol 2022 May 6. Epub 2022 May 6.

Istituto Dermopatico dell'Immacolata, IDI-IRCCS, 00167 Rome, Italy. Electronic address:

Sezary Syndrome (SS) is a rare and aggressive variant of Cutaneous T-Cell Lymphoma. It is characterized by the co-presence of CD4+ neoplastic lymphocytes, named Sezary cells, mainly in the blood, lymph-nodes and skin where they induce chronic inflammation which in turn impairs patients'quality of life and fuels neoplastic cells. No available treatment is resolutive for SS but, immunotherapy is becoming an effective option for this lymphoma. Read More

View Article and Full-Text PDF

Epstein-Barr virus-positive mucocutaneous ulcer, plasmablastic type, associated with nodal CD4+ angioimmunoblastic T-cell lymphoma and generalised pruritus: a self-limiting lymphoproliferative disorder resembling cutaneous plasmablastic lymphoma.

BMJ Case Rep 2022 May 6;15(5). Epub 2022 May 6.

Department of Diagnostic Pathology, Shimada General Medical Center, Shimada, Shizuoka, Japan.

A woman in her 80s reported of generalised pruritus, which was treated with phototherapy and steroid administration. Two months after onset, lymph node biopsy revealed CD4+ angioimmunoblastic T-cell lymphoma with systemic superficial nodal involvement. Intractable prurigo was judged as T-cell lymphoma related. Read More

View Article and Full-Text PDF

The pathophysiology and current treatments for the subcutaneous panniculitis-like T cell lymphoma: An updated review.

Asia Pac J Clin Oncol 2022 May 4. Epub 2022 May 4.

Department of Dermatology, Kaohsiung Veterans General Hospital, Kaohsiung City, Taiwan (ROC).

Subcutaneous panniculitis-like T cell lymphoma (SPTCL) is a rare cutaneous T cell lymphoma, which is indolent in nature but could claim life if not correctly diagnosed and promptly treated. SPTCL is usually presented clinically as painless subcutaneous and erythematous nodules over the trunk or extremities. Active clinical vigilance for these subcutaneous nodules or panniculitis-like lesions is warranted. Read More

View Article and Full-Text PDF

Cutaneous T-cell lymphoma: diagnosing subtypes and the challenges.

Br J Hosp Med (Lond) 2022 Apr 14;83(4):1-7. Epub 2022 Apr 14.

Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK.

Cutaneous T-cell lymphoma is a rare type of extranodal non-Hodgkin's lymphoma that primarily affects the skin. The uncertain pathogenesis and variable clinical presentation make the diagnosis and management of cutaneous T-cell lymphoma a challenge. Cutaneous T-cell lymphoma is a chronic, relapsing illness with treatment aimed at symptomatic relief and improving patient related quality of life. Read More

View Article and Full-Text PDF

Non-pegylated and Pegylated Interferon Alpha-2a in Cutaneous T-cell Lymphoma and the Risk of Severe Ocular Side-effects.

Acta Derm Venereol 2022 May 4. Epub 2022 May 4.

Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, DE-68167 Mannheim, Germany.

View Article and Full-Text PDF

An accurate diagnosis of dermal CD8 lymphoproliferative disorders requires clinicopathological and immunophenotypic correlation.

Authors:
Alejandro A Gru

Br J Dermatol 2022 05;186(5):769-771

Department of Pathology & Dermatology, Cutaneous Lymphoma Program, University of Virginia, Charlottesville, VA, USA.

View Article and Full-Text PDF

[A patient with erythroderma and pruritus: Sézary syndrome].

Ned Tijdschr Geneeskd 2022 02 16;166. Epub 2022 Feb 16.

Maasstad Ziekenhuis, afd. Interne Geneeskunde, Rotterdam.

Background: Erythroderma could be the first sign of a cutaneous T-cell lymphoma (CTCL), such as Sézary syndrome. Causes of erythroderma include inflammatory dermatosis, toxicoderma, paraneoplastic erytroderma, and CTCL. Hence, diagnosing Sézary syndrome can be difficult. Read More

View Article and Full-Text PDF
February 2022

Extranodal NK/T-cell lymphoma primarily presenting as two adjacent slowly growing skin nodules with prominent epidermotropism and CD30 expression, a case report and review of literature.

Dermatol Online J 2021 Dec 15;27(12). Epub 2021 Dec 15.

Department of Dermatology, Indiana University School of Medicine, Indianapolis, Indiana, USA, Division of Hematology/Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA[KA.

Extranodal NK/T-cell lymphoma (NKTCL) is a rarely occurring non-Hodgkin lymphoma with predilection for the nasal cavity. Cutaneous involvement, rarely occurring and often aggressive in behavior, may present as nodular mass-forming lesions with or without ulceration. Histologically, lesions are characterized by an atypical dermal lymphoid infiltrate with angioinvasion and associated necrosis. Read More

View Article and Full-Text PDF
December 2021

Primary cutaneous diffuse large B-Cell lymphoma, leg type mimicking subcutaneous panniculitis-like T-cell lymphoma in a COVID-19 setting: case report and review of literature.

Dermatol Online J 2021 Dec 15;27(12). Epub 2021 Dec 15.

Departamento de Docencia e Investigacion, Escuela de Medicina, Universidad Internacional del Ecuador, Quito, Ecuador Servicio de Patologia, Hospital Metropolitano, Quito, Ecuador.

Primary cutaneous diffuse large B-cell lymphoma, leg type is a rare entity accounting for 4% of all primary cutaneous lymphomas whose clinical presentation encompasses a range of possibilities. COVID-19 has caused a delay in diagnosis of malignant neoplasms and consequently, this has resulted in poorer prognoses. A 62-year-old woman presented with two smooth-surfaced, mobile, well-circumscribed, oval, skin-colored nodules approximately one-cm in diameter with nonerythematous borders on the lower third of the left leg. Read More

View Article and Full-Text PDF
December 2021

Cutaneous T-cell lymphoma developing during nivolumab treatment for metastatic melanoma.

Dermatol Online J 2022 01 15;28(1). Epub 2022 Jan 15.

Division of Dermatology, Tokushima Red Cross Hospital, Komatsushima, Tokushima, Japan.

View Article and Full-Text PDF
January 2022

Care structure of patients with mycosis fungoides and Sézary syndrome in Germany - Care research based on SHI claims data.

J Dtsch Dermatol Ges 2022 05 2;20(5):643-651. Epub 2022 May 2.

Kyowa Kirin GmbH, Düsseldorf.

Background: Cutaneous T-cell lymphomas (CTCLs) are rare forms of non-Hodgkin's lymphoma of T-cell origin that occur mainly in the skin. The most common form is mycosis fungoides (MF), but Sézary syndrome (SS), a more aggressive form of CTCL, is another relevant subgroup. Due to the rare nature of the disease, population-based studies of the epidemiology and disease burden and insights into care delivery are limited. Read More

View Article and Full-Text PDF

The PROCLIPI international registry, an important tool to evaluate the prognosis of cutaneous T cell lymphomas.

Authors:
J J Scarisbrick

Presse Med 2022 Apr 28:104123. Epub 2022 Apr 28.

Department of Dermatology, University Hospital Birmingham, Birmingham, UK. Electronic address:

PROCLIPI is the PROgnostic Cutaneous Lymphoma International Prognostic Index Study with the main aim to produce a prognostic index in mycosis fungoides (MF) and Sezary syndrome (SS). The study prospectively collects clinical, haematological, pathological, imaging, treatment with responses, quality of life and survival data using careful predefined datasets. Patients are subject to a central review to confirm diagnosis. Read More

View Article and Full-Text PDF

Woringer-Kolopp disease (localized pagetoid reticulosis): a systematic review.

Int J Dermatol 2022 Apr 29. Epub 2022 Apr 29.

Wayne State University School of Medicine, Detroit, Michigan, USA.

Objective: Woringer-Kolopp disease (WKD), also known as localized pagetoid reticulosis, is a rare variant of mycosis fungoides as described by the World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) classification system for cutaneous lymphomas. Our objective was to conduct a comprehensive review that describes and evaluates patient demographics, clinical presentation, immunohistochemical findings, management, and outcomes of WKD.

Methods: The databases PubMed, Embase, and Cochrane Library were searched for relevant literature. Read More

View Article and Full-Text PDF

African American and Caucasian patients with Sézary syndrome have no differences in outcomes at an ethnically diverse urban medical center.

Leuk Lymphoma 2022 Apr 28:1-8. Epub 2022 Apr 28.

Department of Hematology, Winship Cancer Institute, Atlanta, GA, USA.

Sézary syndrome (SS) is an aggressive cutaneous T-cell lymphoma with poor survival. We performed a retrospective review of SS patients at Emory University from 1990 to 2020. We collected data on race, clinical characteristics, therapy, and social determinants of health. Read More

View Article and Full-Text PDF

Management of relapsed cutaneous T-Cell lymphoma following allogeneic hematopoietic stem cell transplantation: Review with representative patient case.

Dermatol Ther 2022 Apr 27:e15538. Epub 2022 Apr 27.

Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment option for patients with refractory cutaneous T-cell lymphoma (CTCL) through replacement of the bone marrow responsible for lymphoma cells and possibly induction of a graft-versus-lymphoma effect. However, allo-HSCT is not always curative; relapse of CTCL occurs in about half of patients post-transplant. Treatment of relapsed CTCL after allo-HSCT is challenging because post-transplant patients are at high risk of graft-versus-host disease, and this condition may be precipitated or exacerbated by standard CTCL therapies. Read More

View Article and Full-Text PDF

PCM1-JAK2 Fusion Tyrosine Kinase Gene-Related Neoplasia: A Systematic Review of the Clinical Literature.

Oncologist 2022 Apr 26. Epub 2022 Apr 26.

CellNetix, Seattle, Washington, DC, USA.

Background: This review summarizes the case studies of PCM1-JAK2 fusion tyrosine kinase gene-related neoplasia. Recommended treatment includes JAK2 inhibitors and hematologic stem cell transplantation (HSCT), although the small number of patients has limited study of their efficacy. Herein, we present all available cases in the current searchable literature with their demographics, diagnoses, treatments, and outcomes. Read More

View Article and Full-Text PDF

Development of a Novel Anti-Mouse CCR4 Monoclonal Antibody (CMab-1) by N-Terminal Peptide Immunization.

Monoclon Antib Immunodiagn Immunother 2022 Apr;41(2):87-93

Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.

The CC chemokine receptor type-4 (CCR4) belongs to the G-protein-coupled receptor superfamily, expressed on the cell surface of T cells and its malignancy. Two CCR4 ligands (CCL17 and CCL22) bind to CCR4 that mediate physiological and pathological functions of T cell immune responses. Anti-CCR4 monoclonal antibody (mAb) mogamulizumab is approved for adult T cell leukemia/lymphoma and cutaneous T cell lymphomas. Read More

View Article and Full-Text PDF

Aggressive Primary Cutaneous Anaplastic T-Cell Lymphoma Successfully Treated with Autologous Stem Cell Transplant and Brentuximab Vedotin Consolidation: Case Report and Review of the Literature.

Hematol Rep 2022 Mar 23;14(2):61-66. Epub 2022 Mar 23.

Department of Biomedicine and Prevention, University Tor Vergata, 00133 Rome, Italy.

Primary cutaneous CD30+ lymphoproliferative disorders include primary cutaneous anaplastic large cell lymphoma (pcALCL) and lymphomatoid papulosis. The prognosis of the disease is usually excellent but, in a minority of cases, it presents with extracutaneous involvement and aggressive behavior. The case we present-relapsed after surgical excision, immunosuppressive therapy, and conventional chemotherapy-is the first one treated with Autologous Stem Cell transplant followed by Brentuximab Vedotin consolidation, a scheme already used for high risk Hodgkin Lymphoma. Read More

View Article and Full-Text PDF